Cleveland Biolabs Inc(CBLI)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Market Cap:12.1M; Shares Outstanding:11.3M; Short Interest: 1.01%; Q3 2019(9/30/19): Cash 1.91M Loss 0.45M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -0.32 62.85% -14.29%
2019.3.31 -0.08 27.27% 75.00%
2019.6.30 -0.13 27.78% -62.50%
2019.9.30 -0.17 39.39% -30.77%


Date Sales % last year % last quarter
2018.12.31 1.14M -41.58% 26.67%
2019.3.31 0.2M -13.03% -82.46%
2019.6.30 0.48M -23.30% 140.00%
2019.9.30 0.74M -17.5 54.17%


Insider Transactions:

Institution Ownership:

Total institutions: 17,no change
Shares hold: 450.1k shares. Reduced 0.5K
shares% hold: 3.98%,no change

Analyst Ratings:

Leave a Reply